This review discusses the role of aldosterone antagonists in the treatment of heart failure, including an overview of aldosterone’s role in the pathology of heart failure, the benefits of each ...

Aldosterone escape and non-ACE pathways for angiotensin II production may explain, at least in part, the continued high mortality rates in heart failure patients despite the advances made in ...

Use of an aldosterone antagonist after myocardial infarction has improved outcomes in patients with heart failure with reduced ejection fraction, but whether it benefits others remains unclear.

Aldosterone antagonists (spironolactone ... Spironolactone is indicated (class IIa, level of evidence B) in systolic heart failure with recent or current New York Heart Association functional ...

The aldosterone antagonist eplerenone was evaluated in the Epleronone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) trial, leading to the recommendation for ...

CHICAGO -- A mineralocorticoid receptor antagonist ... acute myocardial infarction (MI) in the modern era, based on the CLEAR OASIS 9 trial. Among heart attack survivors without heart failure ...

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients ...